0001437749-23-008072.txt : 20230327 0001437749-23-008072.hdr.sgml : 20230327 20230327183252 ACCESSION NUMBER: 0001437749-23-008072 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230321 FILED AS OF DATE: 20230327 DATE AS OF CHANGE: 20230327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DARGAN CHARLES K CENTRAL INDEX KEY: 0001112799 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19709 FILM NUMBER: 23765763 MAIL ADDRESS: STREET 1: 8055 W. MANCHESTER AVE. STREET 2: SUITE 405 CITY: PLAYA DEL REY STATE: CA ZIP: 90293 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLARGO, INC. CENTRAL INDEX KEY: 0000880242 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] IRS NUMBER: 650159115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 14921 CHESTNUT ST. CITY: WESTMINSTER STATE: CA ZIP: 92683 BUSINESS PHONE: 888 400-2863 MAIL ADDRESS: STREET 1: 14921 CHESTNUT ST. CITY: WESTMINSTER STATE: CA ZIP: 92683 FORMER COMPANY: FORMER CONFORMED NAME: NUWAY MEDICAL INC DATE OF NAME CHANGE: 20030205 FORMER COMPANY: FORMER CONFORMED NAME: NUWAY ENERGY INC DATE OF NAME CHANGE: 20010815 FORMER COMPANY: FORMER CONFORMED NAME: LATIN AMERICAN CASINOS INC DATE OF NAME CHANGE: 19960520 4 1 rdgdoc.xml FORM 4 X0407 4 2023-03-21 0000880242 BIOLARGO, INC. BLGO 0001112799 DARGAN CHARLES K 18851 NE 29TH AVENUE SUITE 700 AVENTURA FL 3318 1 Chief Financial Officer 0 Option to purchase common stock 0.20 2023-03-21 4 A 0 300000 A 2023-03-21 2033-03-21 Common stock 300000 4331500 D The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 21, 2023, and then (ii) in equal monthly installments of 25,000 shares beginning March 31, 2023, so long as the Engagement Extension Agreement dated March 21, 2023, between Reporting Person and Issuer, remains in force and effect. This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2023, through January 31, 2024. Reporting person was notified on March 27, 2023 of the issuer's approval of the March 21, 2023 extension agreement. /s/ John R. Browning, attorney-in-fact 2023-03-27